Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey
Key result
A survey of the EHRA electrophysiology research network revealed clear practice differences in the use of NOACs for stroke prevention in atrial fibrillation and a need for greater guideline adherence.
Why the study?
What are the current clinical practice patterns regarding the use of NOACs for stroke prevention in atrial fibrillation among European electrophysiologists?
Population
Members of the European Heart Rhythm Association (EHRA) electrophysiology (EP) research network
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
Indicates inconsistent NOAC use for AF stroke prevention; leaves open barriers to guideline adherence and effects on outcomes.
Study Design
Type
Cross-Sectional
Multicenter
Yes
Structured PICO
What are the current clinical practice patterns regarding the use of NOACs for stroke prevention in atrial fibrillation among European electrophysiologists?
P
Population
Members of the European Heart Rhythm Association (EHRA) electrophysiology (EP) research network
I
Intervention
Survey on clinical practice regarding the use of novel oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation
O
Outcome
Clinical practice patterns and guideline adherence in relation to stroke prevention in atrial fibrillation
A survey of European electrophysiologists reveals significant variations in clinical practice and highlights the need for improved guideline adherence regarding NOAC use for stroke prevention in atrial fibrillation.
Cite This Study
Lip et al. (2013) conducted a cross-sectional in Atrial fibrillation. Novel oral anticoagulants (NOACs) was evaluated on Clinical practice in relation to stroke prevention in atrial fibrillation. A survey of the EHRA electrophysiology research network revealed clear practice differences in the use of NOACs for stroke prevention in atrial fibrillation and a need for greater guideline adherence.